The global market for Human Parenteral Nutrition is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Human Parenteral Nutrition market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Human Parenteral Nutrition market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Human Parenteral Nutrition market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Human Parenteral Nutrition market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Human Parenteral Nutrition players cover Baxter, Allergan, Actavis Inc., Otsuka Pharmaceutical Factory, Inc. and Grifols, S.A., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Human Parenteral Nutrition market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Human Parenteral Nutrition market, with both quantitative and qualitative data, to help readers understand how the Human Parenteral Nutrition market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
The study segments the Human Parenteral Nutrition market and forecasts the market size by Type (Carbohydrate Nutrition, Parenteral Lipid Emulsion Nutrition and Single Dose Amino Acid Solution Nutrition), by Application (Hospital, Clinic and Nursing Home,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Parenteral Lipid Emulsion Nutrition
Single Dose Amino Acid Solution Nutrition
Trace Element Nutrition
Vitamins & Mineral Nutrition
Segmentation by application
Segmentation by region
Middle East & Africa
Major companies covered
Otsuka Pharmaceutical Factory, Inc.
B. Braun Melsungen AG
Fresenius Kabi AG
Sichuan Kelun Pharmaceutical Co., Ltd.
Pfizer Inc. (Hospira Inc.)
Chapter 1: Scope of Human Parenteral Nutrition, Research Methodology, etc.
Chapter 2: Executive Summary, global Human Parenteral Nutrition market size and CAGR, Human Parenteral Nutrition market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Human Parenteral Nutrition revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Human Parenteral Nutrition revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Human Parenteral Nutrition market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Baxter, Allergan, Actavis Inc., Otsuka Pharmaceutical Factory, Inc., Grifols, S.A., B. Braun Melsungen AG, Vifor Pharma, Fresenius Kabi AG and Sichuan Kelun Pharmaceutical Co., Ltd. and etc.
Chapter 14: Research Findings and Conclusion